Palmer Joycelynne M.: Blood/Marrow Transplantation for Treat

While treatment is believed to influence disease outcome, the wide variation in published survival and remission rates among chronic myeloid leukemia (CML) patients demonstrates that the effectiveness of treatment appears to be modified by patient characteristics, disease features, and disease management approaches. Future improvements in the treatment of CML are dependent on our ability to distinguish between patients who are likely to have long-term disease free survival and those who are not. Between June 1982 and December 2002, 234 patients with CML in first chronic phase (CP) were treated at the City of Hope National Medical Center with an allogeneic blood or marrow transplant (Allo-BMT) using histocompatible sibling donors. This retrospective case-series study examined the role of patient, disease, and treatment factors collected both at the time of diagnosis and Allo-BMT to assess the predictive value of these factors on a patient?s risk for cytogenetic relapse (CR) and/or death following Allo-BMT. This study also explored the predictive value of three generally accepted prognostic scoring systems (Sokal, Hasford, Gratwohl) in this large single center Allo-BMT population.